螞蟻集團與中大合推校園版「10x1000」金融科技普惠計劃
螞蟻集團宣布,近日與香港中文大學工程學院金融科技應用研究院簽署合作備忘錄,就本港年輕科技人才培訓展開深度戰略合作,雙方計劃於今年下半年合作推出首個校園版「10x1000」金融科技普惠計劃,以配合國家和香港特區政府將香港建設成國際創科中心和推動大灣區發展的大方向。
是次合作預期將增強學界與商界聯繫,共同培育本地金融科技精英,透過「官、產、學、研」相互配合,促進年輕科技人才的培育。根據協議,雙方將合作開展「10x1000」金融科技普惠計劃,獲選的中大學生可參與金融科技相關的網上課程及講座等,並與來自世界各地的業界導師及學員建立網絡、交流知識,為日後從事相關科技工作建立基礎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.